Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy
Open accessThe DOI matches its Crossref record.
Abstract
End-stage hypertrophic cardiomyopathy (ES-HC) has an ominous prognosis. Whether genotype can influence ES-HC occurrence is unresolved. We assessed the spectrum and clinical correlates of HC-associated mutations in a large multicenter cohort with end-stage ES-HC. Sequencing analysis of 8 sarcomere genes (MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3, and ACTC1) and 2 metabolic genes (PRKAG2 and LAMP2) was performed in 156 ES-HC patients with left ventricular (LV) ejection fraction (EF) <50%. A comparison among mutated and negative ES-HC patients and a reference cohort of 181 HC patients with preserved LVEF was performed. Overall, 131 mutations (36 novel) were identified in 104 ES-HC patients (67%) predominantly affecting MYH7 and MYBPC3 (80%). Complex genotypes with double or triple mutations were present in 13% compared with 5% of the reference cohort (p = 0.013). The distribution of mutations was otherwise indistinguishable in the 2 groups. Among ES-HC patients, those presenting at first evaluation before the age of 20 had a 30% prevalence of complex genotypes compared with 19% and 21% in the subgroups aged 20 to 59 and ≥60 years (p = 0.003). MYBPC3 mutation carriers with ES-HC were older than patients with MYH7, other single mutations, or multiple mutations (median 41 vs 16, 26, and 28 years, p ≤0.001). Outcome of ES-HC patients was severe irrespective of genotype. In conclusion, the ES phase of HC is associated with a variable genetic substrate, not distinguishable from that of patients with HC and preserved EF, except for a higher frequency of complex genotypes with double or triple mutations of sarcomere genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical Course and Management of Hypertrophic Cardiomyopathy
Maron, B. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1710575 · Cited by 944
Self-citationHypertrophic obstructive cardiomyopathy
Veselka, J., Anavekar, N. S., & Charron, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31321-6 · Cited by 257
Marstrand, P., Han, L., Day, S. M., Olivotto, I., Ashley, E. A., Michels, M., Pereira, A. C., Wittekind, S. G., Helms, A., Saberi, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044366 · Cited by 219
Self-citationSedaghat-Hamedani, F., Kayvanpour, E., Tugrul, O. F., Lai, A., Amr, A., Haas, J., Proctor, T., Ehlermann, P., Jensen, K., Katus, H. A., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1155-5 · Cited by 173
Pasqualucci, D., Fornaro, A., Castelli, G., Rossi, A., Arretini, A., Chiriatti, C., Targetti, M., Girolami, F., Corda, M., Orrù, P., et al. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001843 · Cited by 93
Self-citation
Metadata
- Authors
- Biagini, E., Olivotto, I., Iascone, M., Parodi, M. I., Girolami, F., Frisso, G., Autore, C., Limongelli, G., Cecconi, M., Maron, B. J., Maron, M. S., Rosmini, S., Formisano, F., Musumeci, B., Cecchi, F., Iacovoni, A., Haas, T. S., Bacchi Reggiani, M. L., Ferrazzi, P., Salvatore, F., Spirito, P., & Rapezzi, C.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 114
- Issue
- 5
- Pages
- 769-776
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2156569889
- Cited by
- 90
- References
- 0
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.amjcard.2014.05.065
- The paper
- Biagini, E., Olivotto, I., Iascone, M., Parodi, M. I., Girolami, F., Frisso, G., Autore, C., Limongelli, G., Cecconi, M., Maron, B. J., Maron, M. S., Rosmini, S., Formisano, F., Musumeci, B., Cecchi, F., Iacovoni, A., Haas, T. S., Bacchi Reggiani, M. L., Ferrazzi, P., . . . Rapezzi, C. (2014). Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2014.05.065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.